Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Caina Technology Co., Ltd. is dedicated to the research, development, manufacturing, and distribution of a variety of medical devices, particularly those related to injections and fluid delivery. The company's product portfolio includes essential sterile and single-use items such as safe, self-destructing syringes, disposable insulin syringes, and sterile insulin pen needles. They also provide sterile needles for blood collection and other specialized sterile medical instruments. Established in 2004, Caina Technology operates from its base in Jiangyin, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.
Target Price
The average target price of 301122.SZ is 36.2 and suggests 23.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to